Focus: Obsidian Therapeutics is a publicly traded biotechnology company focused on cell and gene therapies for oncology, headquartered in Cambridge, MA with 51-200 employees. The company is advancing OBX-115, a cell therapy candidate in Phase 1/2 development for advanced melanoma.
Profile data last refreshed 7h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
4 added, 3 removed. Backfill posture.
Best fit for early-stage cell therapy specialists or operations professionals willing to build infrastructure in a capital-backed but unproven platform.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Obsidian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Obsidian Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Obsidian Therapeutics (OBX) outlines $350M PIPE, Galera mergers and CVR structure - Stock Titan
Obsidian Therapeutics (OBX) outlines $350M PIPE, Galera mergers and CVR structure Stock Titan
Obsidian Therapeutics (OBX) files insider report for director Peter Barrett - Stock Titan
Obsidian Therapeutics (OBX) files insider report for director Peter Barrett Stock Titan
Obsidian Therapeutics (OBX) director details multi-year stock option grants - Stock Titan
Obsidian Therapeutics (OBX) director details multi-year stock option grants Stock Titan
Obsidian Therapeutics (OBX) director Heidi Hagen reports 517,500 option shares - Stock Titan
Obsidian Therapeutics (OBX) director Heidi Hagen reports 517,500 option shares Stock Titan
Obsidian Therapeutics (OBX) CFO Julie Feder reports stock options on 3.0M shares - Stock Titan
Obsidian Therapeutics (OBX) CFO Julie Feder reports stock options on 3.0M shares Stock Titan
Obsidian Therapeutics (OBX) director Maria Fardis reports stock option positions - Stock Titan
Obsidian Therapeutics (OBX) director Maria Fardis reports stock option positions Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.
Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo